Maple Rock Capital Partners’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
Other funds holding CRL
Maple Rock Capital Partners's CRL Position: Q3 2026 in Review
Maple Rock Capital Partners opened a new position in Charles River Laboratories (CRL) in Q3 2026: 466,238 shares worth $138M. The stake represents 2.86% of the portfolio and ranks #12 among its holdings.
642 funds tracked by Wall St. Rank hold CRL as of Q3 2026.
- Maple Rock Capital Partners held 466,238 shares of Charles River Laboratories worth $138M as of Q3 2026.
- Charles River Laboratories was a new Maple Rock Capital Partners position in Q3 2026.
- Charles River Laboratories made up 2.86% of Maple Rock Capital Partners's portfolio in Q3 2026, its #12 holding.
- 642 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.
Based on Maple Rock Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.